There is no single age at which you become eligible for testosterone therapy, because eligibility depends less on how old you are and more on why you need it. A fourteen-year-old boy with delayed puberty, a thirty-year-old man with a pituitary disorder, a transgender man seeking masculinization, and a postmenopausal woman with low sexual desire can all be legitimate candidates, each under different clinical criteria. The common thread is that a documented medical reason must exist before a prescription is written, and the diagnostic workup required to establish that reason shapes the timeline more than any birthday does.
How Testosterone Deficiency Is Diagnosed in Adult Men
For adult men, the most frequent path to testosterone therapy runs through a diagnosis of hypogonadism, which simply means the body is not producing enough testosterone on its own. Guidelines from the American Urological Association require at least two separate blood draws showing low total testosterone, both collected in the early morning when levels naturally peak.1Journal of Urology. Evaluation and Management of Testosterone Deficiency: AUA Guideline The early-morning timing matters because testosterone follows a daily rhythm, dipping in the afternoon and evening.2PubMed Central. PURLS: It’s time to reconsider early-morning testosterone tests A single low reading is not enough for a diagnosis.
What counts as “low” varies slightly depending on the guideline you consult. A large European study defined biochemical hypogonadism as a total testosterone below about 8 nmol/L, with levels between 8 and 12 nmol/L considered intermediate and anything above 12 nmol/L considered normal.3PubMed Central. Testosterone levels and symptoms of hypogonadism in Swedish men: a prospective study from the Vara – Skövde cohort A separate landmark study tied the diagnosis more tightly to symptoms: it concluded that late-onset hypogonadism should be defined by the combination of at least three sexual symptoms alongside a total testosterone below roughly 11 nmol/L and a free testosterone below about 220 pmol/L.4PubMed. Identification of late-onset hypogonadism in middle-aged and elderly men In practice, most American providers use a threshold somewhere around 300 ng/dL (about 10.4 nmol/L), though the cutoff is not absolute.
Blood work alone does not tell the whole story. Your provider will also want to figure out whether the problem originates in the testes themselves (primary hypogonadism, where luteinizing hormone and follicle-stimulating hormone are elevated because the brain is trying harder to stimulate testosterone production) or in the brain’s signaling centers (secondary hypogonadism, where those hormones are low or normal).5PubMed Central. Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests The distinction matters because secondary hypogonadism can sometimes be caused by a pituitary tumor or other treatable condition. In men with mildly elevated prolactin and low testosterone, the ratio between those two values is a useful screening tool for pituitary abnormalities and can help determine whether imaging is warranted.6PubMed. Prolactin-to-Testosterone Ratio Predicts Pituitary Abnormalities in Mildly Hyperprolactinemic Men with Symptoms of Hypogonadism
Adolescent Boys With Delayed Puberty
Testosterone therapy can begin during the teenage years when a boy has constitutional delay of growth and puberty, a condition where puberty simply starts later than average without any underlying disease. Most clinicians hold off until at least age fourteen and a bone age of twelve before prescribing a short course of low-dose testosterone, typically given as monthly injections for about six months.7PubMed Central. Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty One well-known study treated nearly 150 boys, averaging a little over fourteen years old, with 100 mg of testosterone monthly for six months.8PubMed. Testosterone treatment in adolescent boys with constitutional delay of growth and development The idea is to give the body a nudge, not to replace its own production permanently.
Dose matters a lot in adolescents. A meta-analysis of retrospective studies found that low-dose, short-course regimens provided the clearest benefit for final adult height, while medium and high doses did not produce meaningful gains and may have actually shortened the growth window by speeding up bone maturation.9PubMed Central. Effects of androgen therapy on final adult height in boys with constitutional delay of growth and puberty: a meta-analysis of retrospective cohort studies A systematic review confirmed this pattern: at doses of 100 mg or less per month, bone-age advancement in treated boys did not meaningfully outpace chronological age progression, whereas a 200 mg monthly dose caused disproportionate skeletal maturation and reduced predicted final height.10PubMed Central. Testosterone therapy in boys with constitutional delay of growth and puberty: a PubMed-based systematic review and exploratory meta-analysis
One concern with giving testosterone to boys whose own hormone system is still waking up is temporary suppression of natural signaling. A study comparing exogenous testosterone to the aromatase inhibitor letrozole in boys with delayed puberty found that exogenous testosterone suppressed LH, FSH, and a Leydig-cell marker called INSL3 during the first three months, though these levels began recovering even while treatment continued.11PubMed Central. Transient gonadotropin suppression by exogenous testosterone decreases INSL3 in early puberty in boys with constitutional delay of growth and puberty The suppression appears to be transient at low doses, which is one more reason clinicians keep the course short.
Gender-Affirming Testosterone Therapy
For transgender men and transmasculine individuals, testosterone is the primary tool for achieving physical masculinization. Historically, gender-affirming hormones were not started until age sixteen, but more recent Endocrine Society guidelines have moved toward a more flexible age of initiation.12PubMed Central. Gender affirming medical care of transgender youth In practice, the specific age depends on the adolescent’s stage of development, the persistence and consistency of their gender identity, their mental health, and the consent processes in their jurisdiction. For adults, age is rarely a barrier at all.
What does shape the timeline is the assessment model. Two main pathways exist. In the WPATH model, an assessment by a mental health clinician typically comes first. In the informed consent model, a primary care provider works directly with the patient to discuss risks, benefits, and expectations, without requiring a separate mental health referral. One study found that patients assessed by a GP under informed consent started hormones at a median of about one month after their first appointment, compared to roughly three months for those referred through a mental health pathway.13PubMed. The Informed Consent Model of Care for Accessing Gender-Affirming Hormone Therapy Is Associated With High Patient Satisfaction Satisfaction was higher in the GP-assessed group, and interestingly, about 80% of those patients chose to seek mental health support on their own anyway. A separate study noted that WPATH-model clients tended to have more psychiatric diagnoses on record and longer assessments than informed-consent clients.14PubMed Central. Gender-Affirming Hormone Therapy for the Trans, Gender Diverse, and Nonbinary Community: Coordinating World Professional Association for Transgender Health and Informed Consent Models of Care
The effects of testosterone in gender-affirming care include voice deepening, facial hair growth, redistribution of body fat, and cessation of menstruation. These changes are well-documented to have positive physical and psychological effects on the transitioning individual.15PubMed Central. Hormone therapy for transgender patients Some changes, particularly voice deepening and clitoral growth, are irreversible, which is part of why thorough informed consent is central to every access model.
Testosterone for Older Adults
Age-related testosterone decline is one of the most common reasons men seek treatment, and it is also one of the most contested. The FDA tightened its stance on this in 2014, mandating new labeling on testosterone products that limited approved use to hypogonadism caused by specific, identifiable conditions. That made prescribing testosterone purely for age-related decline technically off-label.16PubMed Central. Testosterone therapy in the new era of Food and Drug Administration oversight Despite this, off-label prescribing for aging-related symptoms continued and even trended upward in the years following the FDA’s communication.17PubMed Central. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
The safety picture in older men has been a source of genuine anxiety. One clinical trial in men over sixty-five with limited mobility and testosterone below 350 ng/dL was stopped early because the treatment group had more cardiovascular events: out of 106 men on testosterone, 23 reported cardiovascular-related adverse events. That study’s population, however, had high baseline rates of hypertension, obesity, diabetes, and existing heart disease.18PubMed Central. Is Testosterone Replacement Therapy in Older Men Effective and Safe? A broader meta-analysis of randomized trials in men forty and older with low to low-normal testosterone found that testosterone therapy did not increase rates of death, cardiovascular death, stroke, or heart attack compared to placebo, though it did raise the incidence of cardiac arrhythmias.19PubMed. Long-Term Cardiovascular Safety of Testosterone-Replacement Therapy in Middle-Aged and Older Men: A Meta-analysis of Randomized Controlled Trials The upshot: testosterone in older men is not the cardiovascular catastrophe that early headlines suggested, but it is also not risk-free, and closer monitoring is warranted.
Safety Screening Before and During Treatment
Regardless of your age or reason for starting testosterone, certain baseline checks are standard. A digital rectal exam and a PSA test (a prostate marker) are recommended before starting therapy, with PSA rechecked six to twelve weeks after initiation.20PubMed Central. Rising PSA during Testosterone Replacement Therapy Testosterone does not cause prostate cancer based on current evidence, but it can accelerate the growth of an existing cancer, so screening helps rule out a hidden problem before treatment begins.
The other major monitoring concern is erythrocytosis, an excessive rise in red blood cell concentration. American guidelines recommend against starting testosterone in men with a hematocrit above 50%, while European guidelines set the contraindication threshold at 54%. Both agree that a hematocrit rising above 54% during treatment warrants action.21PubMed Central. Testosterone use causing erythrocytosis If levels climb into a concerning range but remain below that ceiling, switching from injectable testosterone to a transdermal gel or patch can help, as can weight loss, smoking cessation, and treatment of sleep apnea if present.22PubMed Central. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years This applies equally to cisgender men on replacement therapy and transgender men on gender-affirming doses.
Other absolute contraindications include untreated severe sleep apnea, active breast or prostate cancer, and uncontrolled heart failure. These are conditions where starting testosterone would be inappropriate regardless of age or testosterone level.
Fertility Is a Major Consideration for Younger Men
If you are a man of reproductive age, the fertility question should be front and center before you agree to testosterone therapy. Exogenous testosterone suppresses the body’s own hormone signaling chain, which in turn shuts down sperm production. Azoospermia, meaning zero sperm in the ejaculate, can develop within about ten weeks of starting treatment.23PubMed Central. Preserving fertility in the hypogonadal patient: an update Testosterone abuse at supraphysiological doses carries the same risk through the same mechanism.24PubMed Central. Pandemic of testosterone abuse: Considerations for male fertility
Most men recover sperm production within six to eighteen months after stopping testosterone. However, somewhere between 4% and 10% of men who already had impaired spermatogenesis before starting therapy may remain permanently azoospermic.23PubMed Central. Preserving fertility in the hypogonadal patient: an update This is a risk that is often poorly communicated. Many men receive testosterone prescriptions without ever being told it will effectively act as a contraceptive, or that the contraceptive effect might not be fully reversible.
For young men with mildly low testosterone who still want children, alternative medications can raise testosterone without suppressing sperm production. Clomiphene citrate, a drug that stimulates the brain to increase its own signaling to the testes, is often used off-label for this purpose. It has been shown to effectively raise testosterone in young, obese, hypogonadal men.25PubMed Central. Clomiphene Citrate Effectively Increases Testosterone in Obese, Young, Hypogonadal Men Human chorionic gonadotropin (hCG) is another option. Expert recommendations favor trying these alternatives first in young hypogonadal men before resorting to exogenous testosterone.26European Urology Focus. Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male
Testosterone Therapy in Women
Testosterone is not exclusively a male treatment. Postmenopausal women experience a gradual decline in androgen production as ovarian and adrenal function slows, and for some women this contributes to a persistent loss of sexual desire known as hypoactive sexual desire disorder.27PubMed Central. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review International guidelines now endorse low-dose testosterone therapy for postmenopausal women with this condition.28Clinical Journal for Nurse Practitioners in Women’s Health. Testosterone Therapy for Hypoactive Sexual Desire Disorder in Postmenopausal Women
The evidence base is solid for this specific use. A year-long trial of more than 800 postmenopausal women found that a transdermal testosterone patch delivering 300 micrograms per day produced meaningful improvements in satisfying sexual episodes, desire, and personal distress compared to placebo.29PubMed. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen The doses used in women are a fraction of what men receive, and the delivery method is almost always transdermal rather than injectable to avoid the sharp peaks that come with injections. No testosterone product is currently FDA-approved specifically for women, so prescribing in this context is off-label, using compounded formulations or titrating products designed for men down to appropriate doses.
How the Way We Diagnose Testosterone Deficiency Has Changed
The question of when you can start testosterone is inseparable from the question of how the medical establishment decides you need it, and that decision-making process has shifted over the decades. Before reliable blood tests existed, doctors diagnosed testosterone deficiency based on physical signs and symptoms: low energy, poor libido, loss of muscle mass, mood changes. The introduction of the radioimmunoassay in the 1970s made it possible to measure testosterone levels directly, and the field gradually shifted toward relying heavily on those numbers.30Sexual Medicine Reviews. The History of Testosterone and the Evolution of its Therapeutic Potential
That shift had consequences. Some men with clearly low numbers but no symptoms get pushed toward treatment they may not need, while others with textbook symptoms but testosterone levels just above an arbitrary cutoff get turned away. The landmark European Male Aging Study tried to correct this imbalance by insisting that both low numbers and specific symptoms must be present for a diagnosis.4PubMed. Identification of late-onset hypogonadism in middle-aged and elderly men Still, in practice, many clinics treat the lab result as the final word. If you are seeking testosterone therapy and feel that a single blood draw or a borderline number is being used to make a definitive decision, it is reasonable to ask for a repeat test or a more thorough symptom evaluation.
The tension between numbers and symptoms also explains why the online testosterone clinic market has boomed. These direct-to-consumer services often use more liberal diagnostic thresholds or focus heavily on symptom questionnaires. Whether that represents better patient-centered care or overprescribing depends on whom you ask, but the growth of this market has made testosterone more accessible to men who might have been turned away by more conservative providers. It has also made it easier for men with normal levels to obtain prescriptions they do not medically need, which is where the fertility and safety concerns discussed above become especially relevant.
Situations Where Testosterone Therapy Is Clearly Inappropriate
Eligibility is not just about meeting the right criteria. It is also about not meeting the wrong ones. Some situations represent hard stops regardless of your testosterone level or symptoms:
- Active prostate or breast cancer: testosterone can fuel the growth of hormone-sensitive tumors.
- Desire for near-term fertility: as covered above, exogenous testosterone suppresses sperm production, sometimes irreversibly.
- Elevated hematocrit: American guidelines draw the line at 50%, European guidelines at 54%, and both consider levels above 54% a signal to stop treatment entirely.21PubMed Central. Testosterone use causing erythrocytosis
- Untreated severe sleep apnea: testosterone can worsen breathing during sleep in people whose airway is already compromised.
- Uncontrolled heart failure: fluid retention from testosterone can make heart failure worse.
These contraindications apply across all clinical scenarios, whether you are a cisgender man with hypogonadism, a transgender man starting gender-affirming care, or a postmenopausal woman being treated for low desire. They are the reason baseline blood work and a physical exam are non-negotiable steps before any prescription is written, regardless of which access pathway you use.